Table 4. Sensitivity Analyses.
Last Period Outcomes | Main Analysis | V1 | V2 | V3 | V4 | V5 | V6 | V7 | V8 | ||||||||||
Φ(S2b) from 0.7 to 0.5 | Ψ(S2b) from 0.3 to 0.1 | u (S2b) from 0.1 to 0.15 | u (S1 & S2a) from 0.2 to 0.3 | Φ (S2a) from 0 to 0.2 | v from 0.005 to 0.05 | Presence of patients from 0.95 to 0.85 | 2nd line costs from $600 to $400 | ||||||||||||
SFR | LS | SFR | LS | SFR | LS | SFR | LS | SFR | LS | SFR | LS | SFR | LS | SFR | LS | SFR | LS | ||
SZ 2037 | S1 | 5.37 | 27 | 5.37 | 27 | 5.37 | 27 | 5.37 | 27 | 5.16 | 24 | 5.37 | 27 | 5.37 | 27 | 4.52 | 27 | 6.54 | 27 |
S2a | 5.16 | 187 | 5.16 | 187 | 5.16 | 187 | 5.16 | 187 | 4.90 | 148 | 5.92 | 196 | 5.16 | 187 | 4.25 | 187 | 5.98 | 187 | |
S2b | 5.88 | 238 | 5.02 | 233 | 5.56 | 236 | 5.53 | 221 | 5.88 | 238 | 5.88 | 238 | 6.38 | 250 | 5.30 | 238 | 7.04 | 238 | |
CM 2034 | S1 | 2.27 | 52 | 2.27 | 52 | 2.27 | 52 | 2.27 | 52 | 2.15 | 45 | 2.27 | 52 | 2.27 | 52 | 1.87 | 52 | 2.82 | 52 |
S2a | 2.07 | 441 | 2.07 | 441 | 2.07 | 441 | 2.07 | 441 | 2.02 | 361 | 2.37 | 468 | 2.07 | 441 | 1.71 | 441 | 2.42 | 446 | |
S2b | 2.35 | 598 | 2.10 | 584 | 2.18 | 591 | 2.21 | 490 | 2.35 | 598 | 2.35 | 598 | 2.51 | 609 | 2.10 | 598 | 2.87 | 598 | |
TZ 2034 | S1 | 0.64 | 155 | 0.64 | 155 | 0.64 | 155 | 0.64 | 155 | 0.60 | 134 | 0.64 | 155 | 0.64 | 155 | 0.52 | 155 | 0.76 | 155 |
S2a | 0.63 | 1010 | 0.63 | 1010 | 0.63 | 1010 | 0.63 | 1010 | 0.60 | 800 | 0.70 | 1041 | 0.63 | 1010 | 0.52 | 1010 | 0.72 | 1010 | |
S2b | 0.69 | 1334 | 0.62 | 1318 | 0.63 | 1315 | 0.65 | 1243 | 0.69 | 1334 | 0.69 | 1334 | 0.73 | 1388 | 0.61 | 1334 | 0.82 | 1334 |